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Cardiac resynchronization therapy (CRT) is an established treatment for patients with symptomatic heart failure,
severely impaired left ventricular (LV) systolic dysfunction and a wide (> 120 ms) complex. As with any other treat-
ment, the response to CRT is variable. The degree of pre-implant mechanical dyssynchrony, scar burden and scar
localization to the vicinity of the LV pacing stimulus are known to influence response and outcome. In addition to
its recognized role in the assessment of LV structure and function as well as myocardial scar, cardiovascular mag-
netic resonance (CMR) can be used to quantify global and regional LV dyssynchrony. This review focuses on the
role of CMR in the assessment of patients undergoing CRT, with emphasis on risk stratification and LV lead
deployment.
Introduction
The first demonstration of a beneficial effect from car-
diac resynchronization therapy (CRT) was provided by
Cazeau et al who, in 1994, treated a 54 year old heart
failure patient with four-chamber pacing [1]. Subse-
quently, acute hemodynamic studies showed that CRT
improves cardiac output [2,3]. The Multisite Stimulation
in Cardiomyopathies (MUSTIC) study demonstrated
that CRT led to an improvement in NYHA class, quality
of life, exercise capacity and peak oxygen uptake, as well
as to a reduction in heart failure hospitalizations [4]. By
2005, the Cardiac Resynchronization in Heart Failure
(CARE-HF) study of patients with moderate-to-severe
heart failure showed that CRT-pacing (CRT-P) led to a
36% relative reduction in total mortality [5]. The Com-
parison of Medical Therapy, Pacing and Defibrillation in
Heart Failure (COMPANION) study, which included a
similar patient group, had previously shown that addi-
tion of a cardioverter defibrillator (CRT-D) led to an
additional survival benefit [6]. More recently, the Multi-
center Automatic Defibrillator Implantation Trial with
Cardiac Resynchronization Therapy (MADIT-CRT) trial
has shown that compared with implantable cardioverter
defibrillators (ICD) therapy alone, CRT-D therapy is
associated with a dramatic reduction in the risk of
heart-failure events in relatively asymptomatic (NYHA
class I and II) ICD recipients with a low LVEF and wide
QRS complex [7]. The Resynchronization Reverse
Remodelling in Systolic Left Ventricular Ventricular dys-
function (REVERSE) study has shown that CRT leads to
LV reverse remodelling and an increase in LVEF in the
context of milder symptoms (NYHA class I/II) [8]. Stu-
dies are already underway to explore the possible bene-
fits of CRT in patients with conventional indications for
pacing [9] and patients with a narrow QRS duration
[10]. Even if only one of these new indications is added
to current guidelines (Tables 1and 2), the demand for
CRT is likely to increase exponentially over the current
decade.
Appropriate diagnosis and management of heart fail-
ure not only involves an accurate assessment of myocar-
dial and valvular function, but also of heart failure
etiology. Additional aspects that are relevant to CRT are
mechanical dyssynchrony, scar burden and scar localiza-
tion in the vicinity of the LV pacing stimulus. With its
ability to provide a one-stop assessment of all these
aspects of cardiac structure and function, cardiovascular
magnetic resonance (CMR) is gaining credence as a rou-
tine imaging modality for patients undergoing CRT.
This review focuses on the available evidence for using
CMR in the diagnostic work-up and implantation in
patients undergoing CRT. The potential for further
development is also explored.
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Responders and non-responders to CRT
The terms ‘responder’ and ‘non-responder’ are fre-
quently used in relation to CRT. Yet, there is no con-
sensus on what should be considered a response [11].
Some authors use clinical variables, such as an improve-
ment in NYHA class or walking distance, whereas
others use composite measures, such as freedom from
hospitalizations or left ventricular reverse remodelling.
Whilst the notion of response is conceptually attractive,
we should consider the response rate to pharmacological
therapy for heart failure. For example, an improvement
in ≥ 1 NYHA classes is only observed in 46.7% of
patients treated with enalapril, [12] 21% of patients trea-
ted with bisoprolol [13] and 41% of patients treated
with spirinolactone [14]. In relation to placebo, the
responder rates with these drugs are 24.9% for enalapril,
6% for bisoprolol and 8% for spironolactone.
If we are to use ‘response’ in managing patients
undergoing CRT, composite measures are probably the
most useful. The combination of changes in NYHA
class and LV reverse remodelling, for example, is easily
quantifiable and clinically useful. We should consider,
however, that the lack of a symptomatic benefit does
not necessarily imply absence of a prognostic benefit.
Dyssynchrony as the target in CRT
Conducting tissue disturbances give way to conduction
through the slower-conducting myocardium, delays in
ventricular activation, wasted work, [15] a reduction in
cardiac output [16] and LV end-systolic dilatation [17].
According to the most popular paradigm of CRT, cardiac
dyssynchrony arising from such disturbances contributes
to the syndrome of heart failure and its correction leads
to a clinical benefit. This paradigm, which dictates that
pre-implant dyssynchrony is a sine qua non for a benefit
from CRT, has driven the unrelenting search for a
dyssynchrony measure as a predictor of response to and
outcome of CRT.
Echocardiography
In the pursuit for a reliable CMR measure of dyssyn-
chrony, we must consider the extensive body of evi-
dence in relation to dyssynchrony and CRT provided by
echocardiography. Amongst the earliest and the simplest
echocardiographic measures of dyssynchrony to emerge
Table 1 European Society of Cardiology guidelines for cardiac resynchronization therapy (2010 Update)*
Recommendation Patient population Class Level
Sinus rhythm
CRT preferentially by CRT-D is recommended to reduce morbidity or to prevent
disease progression
NYHA class II I A
LVEF ≤ 35%, QRS ≥ 150 ms
CRT-P/CRT-D is recommended to reduce morbidity and mortality NYHA class III/IV I A
LVEF ≤ 35%, QRS ≥ 120 ms
Optimal medical therapy
Atrial fibrillation
CRT-P/CRT-D should be considered to reduce morbidity NYHA class III/IV IIa B
LVEF ≤ 35%, QRS ≥ 130 ms
Permanent dependency induced by AV nodal
ablation
CRT-P/CRT-D should be considered to reduce morbidity NYHA class III/IV IIa C
LVEF ≤ 35%, QRS ≥ 130 ms
Slow ventricular rate and frequent pacing
Concomitant Class I pacemaker indication
CRT-P/CRT-D is recommended to reduce morbidity NYHA class III/IV I B
LVEF ≤ 35%, QRS ≥ 120 ms
CRT-P/CRT-D is recommended to reduce morbidity NYHA class III/IV IIa C
LVEF ≤ 35%, QRS < 120 ms
CRT-P/CRT-D is recommended to reduce morbidity NYHA class II IIb C
LVEF ≤ 35%, QRS < 120 ms
*Recommendations according to presence of sinus rhythm, atrial fibrillation or concomitant conventional pacemaker indications, taken from Dickstein K, et al.
[126] Class and level of evidence is shown in the columns. CRT-P = cardiac resynchronization therapy pacing; CRT-D = cardiac resynchronization therapy -
defibrillation.
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was the septal-to-posterior wall motion delay, [18]
which is the absolute time difference between peak sep-
tal and peak posterior wall motion towards the centre of
the LV. Amongst the most complex is the absolute dif-
ference or the standard deviation of the time-to-peak
systolic wall motion on tissue Doppler imaging in var-
ious (usually 12) myocardial segments [19]. These and
multiple other measures raised great expectations as
predictors of response to and outcome of CRT in early
single-centre studies [18,20,21]. Their utility were
further tested in the Predictors of Response to CRT
(PROSPECT) trial, a multicentre study in which 12
echocardiographic parameters of dyssynchrony were
assessed by a blinded core laboratory in 498 patients
with standard CRT indications [22]. In this study, the
ability of echocardiographic measures to predict clinical
response varied widely, with sensitivities ranging from
6% to 74% and receiver-operator characteristics curves
of ≤ 0.62. Importantly, the interobserver coefficient of
variation for these measures were as high as 72.1% for
the septal-to-posterior wall motion delay and 33.7% for
the standard deviation of the time-to-peak systolic wall
motion of 12 myocardial segments on tissue Doppler
imaging [22]. Essentially, the PROSPECT study found
that no single echocardiographic measure of dyssyn-
chrony improved patient selection for CRT beyond cur-
rent guidelines. In CARE-HF, [5] the first and only
randomized controlled study of CRT to include
measures of dyssynchrony in patients selection, no sin-
gle echocardiographic measure of dyssychrony emerged
as a clinically applicable predictor of outcome. After
much expectation, echocardiographic measures of dys-
synchrony have not gained credence in selecting patients
for CRT [23-26].
Normal QRS duration
The purist view is that there is no treatable dyssyn-
chrony at a QRS < 120 ms and an LVEF > 35%. Dyssyn-
chrony, however, is a biological phenomenon and as
such, is expected to behave as a continuous rather than
as a dichotomous variable [27,28]. Not surprisingly,
therefore, cardiac dyssynchrony is detectable in patients
with a QRS ≤ 120 ms [29-35] and higher LVEFs [36,37].
Using CMR, we have shown that up to 91% of patients
with a QRS < 120 have radial dyssychrony [38]. (Addi-
tional File 1; Movie 1) It seems reasonable to suppose,
therefore, that at least some patients with a QRS < 120
ms might benefit from CRT. Although several observa-
tional studies have reported a benefit in patients with a
QRS < 120 ms, [39-41] the recently reported Resynchro-
nization Therapy in Narrow QRS (RethinQ) study, a
randomized controlled trial, showed no benefit in terms
of peak oxygen consumption [42]. This study, however
did not use an implantation technique that avoids
pacing LV scar. Whether or not CMR-guided CRT
(avoiding scar) is effective in patients with a QRS < 120
ms remains to be explored.
Table 2 American College of Cardiology/American Heart Association/Heart Rhythm Society guidelines for cardiac
resynchronization therapy (2008)*
Recommendation Patient population Class *
CRT-D/CRT-P NYHA Class III/IV I
LVEF ≤ 35%, SR
QRS ≥ 120 ms
Optimal medical therapy





CRT-D/CRT-P NYHA Class III/IV IIa
LVEF ≤ 35%
QRS ≥ 120 ms
Optimal medical therapy
Atrial fibrillation
CRT-D/CRT-P NYHA Class I or II IIb
LVEF ≤ 35%
Optimal medical therapy
Dvice implant with anticipated
frequent ventricular pacing
*Recommendations taken from Epstein AE, et al. [127] Class and level of evidence, according to ACC/AHA/HRS classification, is shown in the column. CRT-P =
cardiac resynchronization therapy pacing; CRT-D = cardiac resynchronization therapy - defibrillation.
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Does the magnitude of pre-implant dyssynchrony affect the
CRT response?
According to the currently accepted paradigm of CRT,
dyssynchrony contributes to the syndrome of heart fail-
ure and its correction by CRT leads to a clinical benefit.
The question arises as to what degree of dyssynchrony is
reversible by CRT. In this respect, we have found that
and that the most severely scarred LVs are the most dys-
synchronous [38] and that extremes of dyssynchrony
relate to a high mortality and morbidity after CRT [34]
These findings suggest that there are extremes of dyssyn-
chrony that cannot be corrected by CRT (Figure 1) [43].
Assessing dyssynchrony with CMR
Except for the UK NICE, [44] no guideline group has
adopted a criterion of mechanical dyssynchrony in rela-
tion to CRT. Importantly, NICE has not specified which
measure of mechanical dyssynchrony should be adopted,
nor what cut-off to apply. In the absence of a consensus,
therefore, measures of mechanical dyssynchrony cannot
be used to decide on eligibility for CRT, even in the UK.
The question remains, however, as to whether measures
of mechanical dyssynchrony can be used for risk stratifi-
cation and for guiding LV lead deployment.
Steady-state free precession (SSFP)
This ‘work-horse’ CMR sequence provides a wealth of
anatomical and functional information that can be used
to derive measures dyssynchrony [34,45]. We have used
conventional SSFP short-axis stacks and semi-automatic
manual planimetry to quantify radial wall motion from
atrioventricular ring to apex. (Figure 2) [34]. Using com-
mercial software (MASS analysis software, Medis, The
Netherlands) each short-axis slice is divided into cords
running circumferentially around the LV. Radial wall
motion is quantified semi-automatically for up to 20
phases in each R-R interval. The time-dependent seg-
mental radial wall motion curve is then smoothed by fit-
ting to an empirical sine wave. The CMR tissue
synchronization index (CMR-TSI) is then calculated as
the standard deviation of all segmental phase shifts of
the radial wall motion extracted from the fit. As shown
in Figure 3, this technique reveals that dyssynchrony is
almost universal in patients with heart failure [38] and
that the CMR-TSI is a better at discriminating between
patients with heart failure and healthy control subjects
than echocardiographic measures of dyssynchrony [38].
Moreover, the CMR-TSI provides prognostic informa-
tion. In a long-term follow-up of 77 patients undergoing
CRT, those with a CMR-TSI ≥ 110 ms were more likely
to meet the endpoints of death from any cause or hospi-
talization for a major adverse cardiovascular event (Fig-
ure 4), death from any cause or hospitalization for heart
failure, and death from cardiovascular causes from car-
diovascular causes than those with a CMR-TSI < 110
ms [34]. These findings represented the first evaluation
of a CMR measure of dyssynchrony against hard clinical
endpoints in patients undergoing CRT. So as not to fall
into the same problems as echocardiographic measures,
[23-25] however, the CMR-TSI requires external valida-
tion before it is adopted in clinical practice.
Figure 1 Paradigms in cardiac resynchronization therapy. Schematic representation of two paradigms of mechanical dyssynchrony in cardiac
resynchronization therapy. The left panel shows a “binary approach”, according to which mechanical dyssynchrony above a certain cut-off is
associated with a benefit from CRT (open circles), whereas dyssynchrony below that cut-off is associated with no benefit (solid circle). The right
panel depicts the “lower/upper cut-off approach”, according to which patients within a finite range of mechanical dyssynchrony benefit from
CRT (open circles), whereas patients with too much dyssynchrony (above the upper cut-off) or too little dyssynchrony (below the lower cut-off)
do not benefit (closed circles). It is hypothesized that, outside the critical range, alternative pacing modes (endocardial pacing, LV pacing with
multiple leads) may be more effective than conventional CRT. Reproduced with permission from Auricchio and Leyva [128].
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Cine SSFP CMR has also been used to derive volu-
metric measures of dyssynchrony. In this regard, Forwalt
et al have employed internal flow (IF) as a measure of the
‘sloshing’ of blood within the LV, reflecting the wasted
work attributable to dyssynchrony. Using this technique,
the LV volume is reconstructed and divided into wedge-
shaped volumes. (Figure 5) Internal flow is defined as the
sum of the magnitude of the volume changes in these
regions minus the magnitude of the global volume
change over each time step in the cardiac cycle: IF(t) = ∑|
ΔV(t)regional| - |Δ∑V(t)regional|. Accordingly, this differ-
ence is zero if no IF has occurred. The IF fraction (IFF) is
defined as the total internal flow as a percentage of stroke
volume. Using this technique, Fornwalt et al found an IFF
of 10 ± 5% in typical CRT patients (NYHA class III or IV,
LVEF < 35%, QRS > 150 ms) and of 1 ± 1% in the healthy
controls (p < 0.001) [46]. An IFF cut-off of 4% discrimi-
nated between patients and controls with 90% sensitivity
and 100% specificity. Again, this SSFP technique is
superior to echocardiographic measures of dyssynchrony
in discriminating between patients with heart failure and
healthy control subjects. Whether or not the IFF predicts
the response and outcome of CRT remains to be
explored.
CMR tagging
To accurately assess myocardial displacement and defor-
mation (strain and strain rate), the imaging region of
interest must be tracked through the cardiac cycle. In
CMR, tacking can be achieved using myocardial tagging
techniques which, in effect, label areas of myocardium.
Essentially, tags, which are created by manipulating
magnetization. [47], act as fiducial markers that conform
to the myocardium in which they are placed. This not
only permits accurate quantification of myocardial dis-
placement, but also of strain and strain rate [48]. Com-
monly used sequences include spatial modulation of
magnetization (SPAMM) and complimentary spatial
modulation of magnetization (CSPAMM). The latter is
Figure 2 Wall motion analysis using SSFP sequences. Wall motion analysis using SSFP sequences involves division of the left ventricular
myocardium into slices and segments (a). The latter extend clockwise from the junction between the interventricular septum and the right
ventricular free wall (beginning of segment 1 and end of segment 6) (b). As shown in (c), the concordance of radial wall motion observed in
healthy control subjects is highly disrupted in patients with heart failure and a left bundle branch block (LBBB).
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more time-consuming, but it allows tags to be analysed
in diastole as well as in systole.
A variety of techniques are available for the analysis of
tagged images [48]. Harmonic phase (HARP, Diagnosoft,
Inc., Palo Alto, California) analysis has recently gained
popularity. This technique involves decomposition into
harmonic magnitude and harmonic phase, which relate
to cardiac structure and tag deformation, respectively.
As the myocardium contracts and the tags get closer,
the tag frequency increases. (Figure 6 and Additional
File 2; Movie 2) This technique has been validated for
the assessment of regional wall motion in animals and
humans [49]. So far, however, HARP-derived indices of
dyssynchrony have not been validated against clinical
outcome measures after CRT.
Most dyssynchrony measures reflect the temporal dis-
persion of cardiac events, measured in terms of the abso-
lute difference or the standard deviation of the time to
Figure 3 Echocardiographic and CMR measures of dyssynchrony in heart failure. Distribution of dyssynchrony measures obtained from
echocardiography and CMR. The standard deviation of the time to peak myocardial sustained systolic velocity (Ts-SD) of 12 left ventricular
segments (a) and the CMR-tissue synchronization index CMR-TSI) (b) in controls and in patients with heart failure (HF), stratified according to
QRS duration. Note the considerable overlap between healthy controls and patients with heart failure. Adapted with permission from a) Yu C-M
et al [30] and (b) Foley et al. [38]
Figure 4 CMR-TSI and outcome of CRT. Kaplan-Meier estimates of the time to the composite endpoint of death from any cause or
hospitalization for a major cardiovascular event (MCE) after CRT.. Patients were stratified according to a pre-implant CMR-TSI < 110 ms or CMR-
TSI ≥ 110 ms. Results of univariate Cox proportional hazards analyses are expressed in terms of the hazard ratio (HR) and 95% confidence limits.
Reproduced with permission from Chalil S, et al. [34]
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onset or peak wall motion, or deformation. In essence,
they reflect temporal dispersion of these parameters. In
addition, the number, or density of segments with late
wall motion or deformation is likely to influence the
hemodynamic effect of dyssynchrony. The so-called
index of regional variance of strain, which is the percent
of regional segments with delayed shortening, [50]
represents a measure of ‘density’ of dyssynchrony.
Importantly, however, this index does not take into
account that for a given magnitude of such an index,
wall motion or deformation can be clustered or evenly
distributed. (Figure 7) In an attempt to circumvent this
problem, Wyman et al used a regional variance vector
of principal strain, according to which a unit vector
sum only has a significant magnitude if delayed versus
early regions are regionally clustered [51]. An alternative
index is the temporal uniformity of strain, [52,53] other-
wise known as the circumferential uniformity ratio esti-
mate (CURE). The methodology used to derive the
CURE involves generating time plots of strain for each
segment in each short axis slice. Each plot of strain ver-
sus myocardial location is submitted to Fourier analysis
to yield zero and first order terms. Using the CURE
index and an animal model of tachy-pacing induced
heart failure, Helm et al showed a spatial concordance
between areas of maximal mechanical synchronization
and areas of optimal LV systolic and diastolic perfor-
mance after CRT (Figure 8) [54]. Bilchick et al have
recently shown that a CURE cut-off of < 0.75 (with 0
denoting pure dyssynchrony and 1 denoting perfect syn-
chrony) predicted improved NYHA class post-CRT with
90% accuracy (positive and predictive values: 87%,
100%) [55]. Whilst these findings are encouraging, mul-
ticentre studies are needed to address whether CURE
not only predicts symptomatic response but also, mor-
bidity and mortality.
Three-dimensional motion and strain
In conventional CMR tagging, tags in the form of an
orthogonal grid are applied in the imaging plane.
Motion analysis is therefore limited to two dimensions.
The LV wall, however, is a complex structure in which
myofibres are arranged in the form of a right-handed
helix in the subendocardium and a left-handed helix in
the subepicardium, with the mid-wall consisting of cir-
cumferential fibres. Such an architecture allows myocar-
dial deformation in multiple planes (Figure 9) [56]. In
LV systole, there is apical counterclockwise rotation and
basal clockwise rotation around the LV long axis. In dia-
stole, there is untwisting of the subendocardial layers,
which contributes to diastolic suction. Simultaneously,
the LV shortens in systole and lengthens in diastole. A
dyssynchrony measure based on only one direction of
motion or deformation may not necessarily reflect the
extent of LV mechanical dysfunction.
Xu et al have recently developed a three-dimensional
CMR tagging sequence and an optical flow method to
measure three-dimensional LV wall deformation in a
single cine acquisition [57]. As shown in Figure 10, this
technique allows quantification of strain as well as direc-
tion of myocardial deformation. Although it has only
been applied in animals, it is likely to prove useful in
the field of CRT.
Figure 5 Derivation of the internal flow fraction. (a) For the calculation of internal flow fraction, the three-dimensional LV volume is
superimposed on the four-chamber long-axis and short axis SSFP images and the left ventricle is divided into 16 wedge-shaped regional
volumes. (b) the Internal Flow Fraction discriminates between patients and healthy controls with 95% accuracy. Reproduced with permission
from Fornwalt BK, et al. [46]
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Other techniques
Various CMR techniques can be used to assess dyssyn-
chrony from myocardial velocity measurements. In this
respect, we should note the limitations of velocity-based
measurements in the assessment of dyssynchrony, as
demonstrated by echocardiographic studies [23,58].
Velocity-encoded CMR has shown some promise in the
assessment of dyssynchrony [59]. In a small study, Mar-
san et al found a strong correlation between tissue Dop-
pler imaging and velocity-encoded CMR with respect to
longitudinal myocardial peak systolic and diastolic veloci-
ties and time to peak systolic velocity at the level of left
ventricular septum and lateral walls. (r = 0.97, p < 0.001)
[60] Similar findings emerged from a study of patients
with idiopathic dilated cardiomyopathy [61].
Strain-encoded (SENC) CMR has recently emerged as
a technique for directly imaging strain without the need
for post-processing [62]. It uses a standard tagging
sequence that tags myocardium at end-diastole with a
sinusoidal tag pattern which modulates the longitudinal
magnetization orthogonal to the imaging plane. Myocar-
dial deformation leads to changes in the local frequency
of the tag pattern in proportion to strain. As well as
providing real-time quantitative strain measures, SENC
has a higher spatial resolution than standard tagging
and allows acquisition of both circumferential and longi-
tudinal myocardial strain data. So far, however, this pro-
mising technique has not been applied to CRT.
Atrioventricular and interventricular dyssynchrony
The above CMR techniques are useful for the assessment
of intraventricular dyssynchrony. Interventricular dyssyn-
chrony, however, is also relevant in CRT. In a study of 45
patients undergoing CRT, Muellerleile et al found that the
interventricular mechanical delay, derived from velocity-
Figure 6 Relationship between strain and tag frequency for harmonic phase-based strain measurements. A)Contraction of a tagged fibre
in the middle increases the tagging frequency (density of tag lines), as shown for the top fibre. Stretching causes a reduction in local frequency.
(B) Two-dimensional segmentation of the heart and mesh generation (top panel) and regional strain versus time plots over the cardiac cycle; (C)
complete regional strain versus time plots over the cardiac cycle for all segments. ECC = circumferential strain. Reproduced with permission from
Lardo et al. [129]
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encoded CMR, was comparable to pulsed-wave echocar-
diography in predicting responders to CRT [63].
The role of atrioventricular dyssynchrony in predicting
the response to CRT has not been studied. Arguably,
correction of atrioventricular dyssynchrony should relate
to a favourable response. Whilst atrioventricular
dyssynchrony is easily measured with echocardiography,
this is still challenging for CMR.
Dyssynchrony and LV pacing site
Several studies have shown that the anatomical position
of the LV lead during CRT, assessed using fluoroscopy,
has no bearing on the response to and outcome of CRT
Figure 7 Dyssynchrony indexes and regional distribution of wall motion. Schematic representation of net dyssynchrony based on spatial
distribution of delayed activation. When regions of delayed activation are clustered, the net impact on dysfunction is greater than when they
are dispersed. Both situations are associated with similar overall numbers of delayed segments overall, as well as similar variance and
dyssynchrony indexes. In contrast, a vector index would be zero for dispersed dyscoordinate shortening but non-zero when dyscoordinate
motion is spatially clustered. Reproduced from Helm RH, et al. [52]
Figure 8 Concordance between the CURE index and mechanical resynchronization. A) Three-dimensional plot of relative mechanical
activation time (time from QRS to peak circumferential strain) in a dog model of a dyssynchronous failing heart (with left bundle-branch block)
and during CRT (biventricular pacing). The green dot shows the LV stimulation site. B) Synchrony indexed by CURE was calculated as a function
of varying LV pacing site and plotted on three-dimensional maps, in which the colour red denotes optimal mechanical resynchronization.
C) Combined maps derived for ventricular stroke work and synchrony (CURE) were determined in four failing hearts, and the territories
producing optimal responses (70% maximal) for both were calculated and are displayed in green (far right). Adapted from Helm RH, et al. [54]
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[64-66]. Small echocardiographic studies using tissue
Doppler imaging, [67] tissue synchronization imaging
(TSI), [68] three-dimensional echocardiography, [69]
and speckle tracking, [70] however, have shown that a
better response to CRT can be achieved if the LV lead
is deployed in the area of latest activation or contrac-
tion. There is, nevertheless, a wide interindividual varia-
tion with respect to the site of latest activation [67-70].
Using the combination of pressure-volume loops and
myocardial tagging to assess the ideal LV position in
pacing-induced failing canine hearts, Helm et al found
that LV sites yielding 70% of the maximal dP/dtmax
increase covered approx. 43% of the LV free wall [54].
The distribution and size of these pacing sites correlated
with the three-dimensional dyssynchrony mapping
derived from myocardial tagging. Essentially, this study
provided proof of concept that myocardial tagging can
be used to locate the ideal site for LV lead deployment
in CRT. Importantly, however, this animal model did
not involve myocardial infarction. Rademakers et al, on
the other hand, have recently devised an animal model
of heart failure involving myocardial infarction [71].
This model revealed that CRT can improve resynchroni-
zation and LV pump function to a similar degree in
Figure 9 Twist mechanics of the left ventricle. Following electrical and mechanical activation in the apical subendocardial region, there
follows a period of left ventricular isovolumic contraction (IVC), during which (A), the subendocardial myofibers (right-handed helix) shorten with
stretching of the subepicardial myofibres (left-handed helix) to effect clockwise rotation of the apex and counterclockwise rotation of the base.
During ejection (B), there is simultaneous shortening of the subendocardial and subepicardial layers. The larger arm of moment of the
subepicardial fibers dominates the direction of twist, causing counterclockwise and clockwise rotation of the apex and base, respectively. During
isovolumic relaxation (IVR) (C), subepicardial fibres lengthen from base to apex and subendocardial fibres lengthen from apex to base. In diastole,
there is relaxation in both layers, with minimum untwisting (D). Reproduced with permission from Sengupta PP, et al. [56]
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infarcted than non-infarcted hearts, but optimal lead
positioning and timing of LV stimulation was crucial. In
clinical practice, it is likely that combining three-dimen-
sional myocardial tagging with an assessment of scar
will be useful in guiding LV lead deployment.
Dyssynchrony mapping
If deploying the LV lead in an area of late activation or
contraction is indeed important, it is in the interest of
the CRT implanter to know how many areas there are
and where they are. In this respect, we should consider
that the myocardium is a complex anisotropic fibre
structure, consisting of longitudinal, circumferential and
oblique layers that form a mechanical link between
remote areas of the myocardium [72-74]. The myocar-
dium is also electrically heterogeneous from endo-
cardium to mid-myocardium and epicardium [75].
Conduction disturbances, superimposed on the inherent
anatomical, functional and electrical heterogeneity of the
myocardium is likely to lead to multiple areas of dyssyn-
chrony [76,77].
Using in-house software written in MatLab (MatLab,
The Mathworks Inc, MA; freely available from the
author), we have used the phase of inward radial wall
motion data derived from short axis SSFP slices to build
colour-coded maps of radial wall motion (Figure 11)
[38]. The spatial distribution of late inward radial
motion was quantified by manually counting the num-
ber of patches with 180° phase shifts. We found that, in
patients with ischemic cardiomyopathy, late inward
radial motion is distributed in a patchy manner
throughout the LV (Additional Files 3 and 4; Movies 3
and 4). This finding raises the possibility that deploying
an LV lead over a single site of late wall motion may
not correct global cardiac dyssynchrony. By the same
token, multiple LV leads may be preferable to one LV
lead in some patients, eg. non-responders to one LV
Figure 10 Three-dimensional tagging and optical flow methodology. Images from a technique involving a three-dimensional CMR tagging
sequence and an optical flow method to measure three-dimensional LV wall deformation in a single cine acquisition. Panels A to C illustrate the
maximum principal strain (ε1) on three representative short axis slices. The colour of the plot and the length of the overlaid line segments
correspond to the magnitude of the strain while the direction is indicated by the vector. The images show the minimum ε1 in the septum and
the maximum ε1 in the lateral wall. Panel D shows a mid-wall surface colour-coded by with ε1, with superimposed eigenvector direction at four
longitudinal levels. Note that ε1 is directed towards the centre of the LV, indicating in-plane radial thickening.
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lead [78]. Admittedly, this is speculative but may never-
theless be relevant to LV lead deployment.
Myocardial scar and CRT
The effectiveness of almost all cardiac therapies is
dependent on myocardial viability. Such is certainly the
case for revascularization [79-84] and pharmacological
therapy [85]. With respect to CRT, the total amount of
scar (scar burden), its location and relationship to the
pacing stimulus have been shown to be important in
determining response and outcome. It is by virtue of
unique anatomical resolution and the contrast between
scarred and non-scarred myocardium achievable
[81,86,87] that CMR has become the gold-standard for
the in vivo assessment of myocardial scarring.
Scar burden
Several studies have shown that scar burden relates to a
poor response to and outcome from CRT. In a LGE-
CMR study of 28 patients undergoing CRT, White et al
found that scar burden was higher in the non-respon-
ders versus responders group (median 24.7% vs. 1.0%,
respectively, p = 0.0022) [88]. In a study of 45 patients
with ischemic cardiomyopathy, we showed that scar
burden correlated negatively with changes in 6-min
Figure 11 Radial wall motion mapping with CMR. The phase of inward radial wall motion is represented by colours ranging from blue (zero
phase shift: inward motion during global systole), to green (90° phase shift: inward motion at the end of global systole) and to red (180° phase
shift: inward motion during global diastole). Accordingly, the bull’s eye with a homogenous blue colour throughout denotes complete
synchrony, whereas a bull’s eye with a homogenous red colour throughout denotes complete synchrony. Heterogenouss colour coding denotes
dyssynchrony of radial motion, with blue representing early (global systolic phase) activation and red representing late (global diastolic phase)
inward radial wall motion. Note the patchy distribution of wall motion throughout the LV. Reproduced with permission from Foley P, et al. [38]
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walking distance (r = -0.54, p < 0.0001) and positively
with changes in quality of life scores (r = 0.35, p =
0.028; high scores denote a poorer quality of life). The
response (defined as survival for one year following
implantation free of hospitalizations plus an improve-
ment by ≥ 1 NYHA classes or by ≥ 25% in 6-min walk-
ing distance) in patients with < 33% scar was 2.3 times
greater than in patients with ≥ 33% scar [89]. In a
further study of 62 patients undergoing CRT, we found
that the presence of a LV free wall scar was as an inde-
pendent predictor of the composite endpoints of cardio-
vascular death or hospitalization for worsening heart
failure [HR: 3.06, P < 0.0001)] as well as the endpoint of
cardiovascular death [HR: 2.63, P = 0.0016)] after a
mean follow-up period of 2 years. These findings are in
keeping with those of a study using 201Tl single photon
emission computed tomography (SPECT), [90] in which
scar burden was shown to correlate negatively with
changes in LVEF after CRT (r = -0.53; P < 0.0001).
The cut-off of scar burden above which CRT becomes
ineffective is difficult to identify from the various stu-
dies. This is partly due to the adoption of different cri-
teria for response to CRT and the inclusion of varying
proportion of patients with ischemic and non-ischemic
cardiomyopathy. For example, in our study of only
patients with ischemic cardiomyopathy, [89] a scar
volume of 33% was the best cut-off for predicting a
favourable response: the responder rate in patients with
< 33% scar was 2.3 times greater than patients with ≥
33% scar. In contrast, White et al, who studies patients
with ischemic (52%) and non-ischemic cardiomyopathy,
found a scar burden < 15% as the best cut-off for pre-
dicting a clinical response [88]. Taken together, these
studies of myocardial scarring and CRT support the
hypothesis that there is a limit of scar burden above
which resynchronization becomes ineffective.
Scar transmurality
In the field of revascularization, myocardial segments with
transmural scar respond poorly to revascularization [81].
We used LGE-CMR to assess the clinical effects of
increasing transmurality of myocardial scars in LV free
wall, the site of LV lead deployment in CRT. In a study
patients with ischemic cardiomyopathy, a transmurality
exceeding ≥ 51% in a LV free wall scar was associated with
a poor response rate (23%), compared with scars with <
51% transmurality (88%, p < 0.001), in terms of a compo-
site clinical score (survival for 1 year with no heart failure
hospitalizations, and; improvement by ≥ 1 NYHA classes
or ≥ 25% 6-min walking distance). In multivariate analyses,
transmurality of LV free wall scars emerged as a negative
predictor of clinical outcome after CRT. (Figure 12) [89].
Scar location and relationship to LV pacing site
Intuitively, viability the paced LV segment could influ-
ence the outcome of CRT. This notion is supported by
the fact that a pacing stimulus in scarred myocardium
leads to a prolonged and fragmented QRS complex
[91,92] as well as electrical and mechanical dyssyn-
chrony. Furthermore, it is known that myocardial scars
are not readily excitable [93] and that they effectively
reduce the volume of myocardium available to a LV
pacing stimulus [94]. In line with these findings, we
have shown that pacing outside the LV free wall scar is
associated with a better response than pacing over the
scar (86% vs 33%, p = 0.004) (Figure 13). Another study
showed that pacing scar was associated with a higher
risk scar of cardiovascular death or heart failure hospita-
lization [81% vs 24%, p = 0.0009)], compared with
pacing non-scar. (Figure 14) [95] These findings are in
Figure 12 Effect of scar transmurality on outcome after CRT. Kaplan-Meier estimates of the time to clinical endpoints in patients with non-
LV free wall scars, transmural LV free wall scars and non-transmural LV free wall scars. Adapted from Chalil S, et al. [89]
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keeping with those of a study involving 201Tl single
photon emission computed tomography, in which scar
density in the segments in the vicinity of the LV lead
was lower in responders versus non-responders
(response defined as a ≥ 15% increase in LVEF) [90].
Following the finding that pacing LV free wall scar is
detrimental in CRT is the use of LGE-CMR to guide LV
lead deployment has become standard practice in some
centres. In the author’s implanting experience, scarring
over the entire LV free wall is a rare occurrence and it
is unusual not to have coronary sinus tributaries over
non-scarred myocardium.
Composite predictors
Heart failure is a complex syndrome that can hardly be
quantified in terms of a single parameter. Accordingly,
it is perhaps folly to consider that one single parameter
can be used to predict the response and outcome of
CRT. Clearly, the outcome of heart failure and CRT are
intimately dependent on a panoply of factors, not all of
which relate to hemodynamic or imaging parameters. It
is this which provides the biological rationale for using
composite predictors. The statistical attraction is that
composite predictor tends to dampen the background
noise of sampling error [96].
Figure 13 Effect of LV pacing site scar on the clinical response to CRT. Box and whisker plots of changes in 6-min walking distance and
quality of life (QoL) in patients with LV free wall scars, grouped according to relationship of LV pacing lead tip to scar or non-scar. The five
horizontal lines represent the 10th, 25th, 50th, 75th and 90th percentiles of each variable, from bottom to top. Reproduced from Chalil S, et al.[89]
Figure 14 Effect on clinical outcome of pacing LV free wall scar in CRT. Kaplan-Meier estimates of the time to cardiovascular death or
hospitalization for heart failure in patients with a LV free wall scar, grouped according to whether the LV lead was deployed over the scar or
outside the scar. Hazard ratios and 95% confidence intervals derived from univariate Cox proportional hazards analyses are shown in
parentheses. The right sided panels show representative short axis LGE-CMR slices of lead deployments on the scar and outside the scar.
Adapted from Chalil S, et al. [95]
Leyva Journal of Cardiovascular Magnetic Resonance 2010, 12:64
http://www.jcmr-online.com/content/12/1/64
Page 14 of 22
Figure 15 Combined dyssynchrony and scar maps. Endocardial wall motion and scar were quantified using SSFP and LGE-CMR, respectively.
The color-encoded regional delay of radial inward motion is mapped onto a bull’s eye map and LV model, pictured from above (middle figure)
and below (bottom figure). Timing of radial inward motion is expressed as a phase delay ranging from zero to 180°. A phase delay of zero
represents early ventricular motion concordant with initial electrical activation and is colour coded blue, while a phase delay of 180° denotes
diastolic inward motion and is colour coded red. The LV free wall scar (grey-black) is superimposed on the endocardial wall motion map. In the
figure, the LV septum is contracts early in systole and the inferior wall close to the LV free wall scar shows abnormal diastolic radial inward
motion. Note the patchy distribution of wall motion throughout the left ventricle. Reproduced with permission from Foley P, et al. [38]
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In patients not treated with CRT, composite predic-
tors have been shown to be superior to single para-
meters in prognostic risk assessment [97-99]. We have
recently evaluated 16 risk factors in relation to mortality
and morbidity in 148 patients undergoing CRT [100].
These risk factors included the CMR-TSI scar location,
derived from SSFP and LGE-CMR, respectively. (Figure
15) In Cox proportional hazards analyses, CMR-derived
Dyssynchrony, LV Scar location and Creatinine (the
DSC index) emerged as independent predictors of cardi-
ovascular mortality. The DSC index, derived from these
variables combined, emerged as a powerful predictor of
cardiovascular mortality. Compared with patients with a
DSC < 3, cardiovascular mortality in patients in the
intermediate (DSC index: 3 to 5; HR: 11.1) and high
(DSC index ≥ 5; HR: 30.5) were higher (Figure 16).
These findings illustrate that combining known predic-
tors of cardiovascular death in patients with heart fail-
ure, such as creatinine, [98,101-104] with variables
which are known to be pathophysiologically linked to
CRT, such as dyssychrony and LV scar, improves the
ability to predict outcome. Other groups have also used
combined measures to predict the response to CRT. Bil-
chick et al, for example, found that adding LGE-CMR
scar data (< 15% scar) to a dyssynchrony measure (in
the form of the CURE index) improved the ability to
predict an improvement in NYHA class after CRT [55].
CMR and etiology of heart failure
Heart failure is not a diagnosis without qualification of
etiology [105]. The etiology of heart failure influences
prognosis and the choice of therapy, including device
therapy. In this respect, the 2007 UK National Institute
of Clinical Excellence (NICE) guidance stipulated that
CRT-D should only be considered if there is a history of
a myocardial infarction, or ‘a familial cardiac condition
with a history of sudden death, including long QT syn-
drome, hypertrophic cardiomyopathy, Brugada syn-
drome or arrhythmogenic right ventricular dysplasia, or
have undergone surgical repair of congenital heart dis-
ease’ [44]. Idiopathic dilated cardiomyopathy, which
accounts for most cases of non-ischemic cardiomyopa-
thy, was not considered by NICE and therefore, falls
under the guidance for CRT-P. In the UK, therefore,
etiology is particularly important in choosing between
CRT-P or CRT-D. Importantly, however, an ischemic
etiology does not imply reduced prognostic benefit from
CRT [106].
The diagnosis of ischemic cardiomyopathy has tradi-
tionally been made on the basis of a history of a myo-
cardial infarction, [107] the finding of coronary artery
stenoses on coronary angiography or of a regional wall
motion abnormalities on echocardiography. It is well
recognized, however, that myocardial infarctions can be
silent (28% in men, 35% in women), [108] that coronary
angiography can be normal after a myocardial infarction
(8%) [109,110] and that wall motion abnormalities are
not exclusive to ischemic cardiomyopathy [111].
Unparalelled anatomical imaging, coupled with the
findings of late gadolinium enhancement (LGE)-CMR,
[112,113] makes CMR an ideal, radiation-free investiga-
tion for the investigation of heart failure etiology. (Fig-
ure 17) Typically, a myocardial infarction leads to
scarring in subendocardial or transmural distribution
along arterial territories. In contrast, non-ischemic car-
diomyopathy is characterized by a lack of localized
Figure 16 The DSC index as a composite predictor of outcome after CRT. Graph shows Kaplan-Meier estimates of the time to
cardiovascular death. Patients were stratified according to pre-implant Dyssynchrony, left ventricular free wall Scar and Creatinine (DSC) index.
The event rate, number of patients in the DSC risk stratum and the% event rate are shown in parentheses. The hazard ratio (HR) and 95%
confidence intervals are also shown. Reproduced with permission from Leyva F, et al. [130]
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myocardial scarring or less often, by mid-wall LGE,
denoting fibrosis [86,87,114]. A patchy distribution of
LGE is found in myocarditis, sarcoidosis and arrhythmo-
genic right ventricular cardiomyopathy. Diffuse LGE is
characterisitic of amyloidosis and Anderson-Fabry
disease.
The sequences used to quantify T2* have proven to be
unique in the identification and management of iron
overload cardiomyopathy, [115] Sequences using T2-
weighting have also been used to identify myocardial
oedema, [116,117] which may be useful in the assess-
ment of myocarditis and acute coronary syndromes
[110,87].
CMR device compatibility
As discussed above, the principal role of imaging in
CRT is in selecting patients and in guiding device
implantation. Potential aspects of imaging after device
implantation, such as residual dyssynchrony and rela-
tionship of myocardial scarring to the implanted LV
lead may help identifying the reasons for a lack of
response.
Several factors preclude the use of CMR in patients with
devices [118]. Radiofrequency-induced heating of the
pacing leads has been shown to lead to temperatures as
high as 60° in experimental settings [119]. On the other
hand, radiofrequency and magnetic gradients induce cur-
rents within the device generator [120] and these can
interfere with detection and pacing algorithms. In addi-
tion, they can induce arrhythmias and alter pacemaker set-
tings. These factors have indeed implicated in the reported
deaths. Despite these concerns, several centres have
recently reported favourably on the safety of CMR in
patients with pacemakers [121,122]. Continuous ECG,
blood pressure and oxygen saturation monitoring during
the scan, turning off the device in non device-dependent
patients, setting the leads to a bipolar configuration and
using low field, gradient and radiofrequency settings are
among the precautionary measures taken. With regard to
CRT-D and ICDs, experience is more limited. In balance,
the strength of the evidence for a role of CMR in CRT is
insufficient to justify scanning after implantation.
This year has seen the launch of the first CMR-safe
pacemaker (Medtronic Inc, Minneapolis, US). The
development of CMR-safe CRT-P and CRT-D devices
would permit assessment of cardiac function, dyssynch-
orny and myocardial viability after device implantation.
This is not only likely to help in clinical management
but it will undoubtedly further our understanding of the
mechanisms underlying CRT.
Intraoperative CMR in CRT
Recently, Schwatzman have shown how myocardial scar,
imaged pre-operatively using LGE-CMR, can be fused
with electroanatomic mapping data to guide LV lead
implantation [123]. Using this technique, activation time
Figure 17 Assessment of heart failure etiology with CMR. A) LGE-CMR short axis slice showing a subendocardial myocardial infarction in the
territory of the left anterior descending artery; B) LGE-CMR short axis slice showing a transmural myocardial infarction the territory of the
circumflex artery; C) LGE-CMR showing a transmural myocardial infarction in the territory of the right coronary artery, which is associated with
marked myocardial thinning.; D) Patchy LGE characteristic of myocarditis.; F) Mixed cardiomyopathy: left ventricular non-compaction
cardiomyopathy and ischemic cardiomyopathy. Note the transmural inferior myocardial infarction (see insert for LGE-CMR) which has led to
myocardial thinning.; G) Four-chamber and short-axis LGE-CMR images showing mid-wall LGE, denoting fibrosis, in idiopathic dilated
cardiomyopathy.
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and virtual venography was used to target LV lead posi-
tions, and the electroanatomic mapping system was
used to assist in lead manipulation. Further studies,
however, are needed to determine whether other CMR-
derived data, relating to coronary sinus anatomy, [124]
mechanical activation, [125,34] perfusion and viability
can also be ‘fused’ with real-time CMR or conventional
fluoroscopy to guide LV lead deployment.
Conclusions
This decade is likely to see an exponential growth in the
use of CRT for patients with heart failure. CMR not
only provides unparalleled quality of imaging for cardiac
structure and function but it is also unique in differen-
tiating between the various causes of LV dysfunction. It
is on this basis that CMR is already considered as an
ideal ‘one-stop’ investigation for patients with heart fail-
ure. In addition, perhaps the most clinically applicable
aspect of CMR to CRT per se is its ability to precisely
localise myocardial scar, which is known to be crucial in
LV lead deployment. For these reasons, CMR has a
clear role in the diagnostic and implantation pathway of
patients undergoing CRT. Further studies are needed to
clarify the utility of fusion imaging in guiding LV lead
deployment. On the part of scanner manufacturers,
further software development and validation is required,
so as to make analysis of dyssynchrony, tagging and
LGE data more accessible to the clinician. With the
development of CMR-compatible devices, the use of
CMR in CRT device optimization may one day become
a reality.
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Additional material
Additional file 1: Movie 1. Four-chamber cine SSFP in a patient with
idiopathic dilated cardiomyopathy and a QRS of 98 ms, illustrating how
visually-detectable dyssynchrony can also occur in patients with a narrow
QRS complex.
Additional file 2: Movie 2. Shows colour-coded analysis of myocardial
tags using HARP. x-coordinate represents time frames, y-coordinate
represents percent circumferential shortening (% Ecc). Reproduced with
permission from Shehata ML, et al [48]
Additional file 3: Movie 3. Colour-coded endocardial wall motion
throughout the cardiac cycle in a healthy subject, derived from SSFP
imaging. Note the homogeneity of colour (early wall motion in blue and
late wall motion in red) throughout the cardiac cycle.
Additional file 4: Movie 4. Colour-coded endocardial wall motion
throughout the cardiac cycle in a patients with heart failure and a left
bundle branch block, derived from SSFP imaging. Note the
heterogeneity of colour (early wall motion in blue and late wall motion
in red) throughout the cardiac cycle.
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